Sun Pharma (Sun)’s Q2FY24 performance was lower than our expectation (though in line with Street) due to higher overheads and lower sales of gRevlimid. Traction in branded generics business across India, emerging markets and RoW coupled with specialty business in US led to 11.3% growth in revenue.